Bhuvana A. Setty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bhuvana A. Setty has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Brett G. Klamer
Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
2 shared publications - Jennifer K. Matsui
College of Medicine, The Ohio State University, Columbus, OH 43210, USA
2 shared publications - Joshua David Palmer
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2 shared publications - Nicholas D. Yeager
Nationwide Children’s Hospital
2 shared publications - Ryan David Roberts
Nationwide Children's Hospital, Columbus, OH
2 shared publications - Sujith Baliga
Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2 shared publications
Latest Publications
- Open Access
Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes with the use of SABR in our pediatric solid tumor population. Methods: This was a single-institutional study in patients < 30 years treated with SABR. The primary endpoint was local control (LC), while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. The survival analysis was performed using Kaplan–Meier estimates in R v4.2.3. Results: In total, 48 patients receiving 135 SABR courses were included. The median age was 15.6 years (interquartile range, IQR 14–23 y) and the median follow-up was 18.1 months (IQR: 7.7–29.1). The median SABR dose was 30 Gy (IQR 25–35 Gy). The most common primary histologies were Ewing sarcoma (25%), rhabdomyosarcoma (17%), osteosarcoma (13%), and central nervous system (CNS) gliomas (13%). Furthermore, 57% of patients had oligometastatic disease (≤5 lesions) at the time of SABR. The one-year LC, PFS, and OS rates were 94%, 22%, and 70%, respectively. No grade 4 or higher toxicities were observed, while the rates of any grade 1, 2, and 3 toxicities were 11.8%, 3.7%, and 4.4%, respectively. Patients with oligometastatic disease, lung, or brain metastases and those who underwent surgery for a metastatic site had a significantly longer PFS. LC at 1-year was significantly higher for patients with a sarcoma histology (95.7% vs. 86.5%, p = 0.01) and for those who received a biological equivalent dose (BED10) > 48 Gy (100% vs. 91.2%, p = 0.001). Conclusions: SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.
Open AccessDisease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes with the use of SABR in our pediatric solid tumor population. Methods: This was a single-institutional study in patients < 30 years treated with SABR. The primary endpoint was local control (LC), while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. The survival analysis was performed using Kaplan–Meier estimates in R v4.2.3. Results: In total, 48 patients receiving 135 SABR courses were included. The median age was 15.6 years (interquartile range, IQR 14–23 y) and the median follow-up was 18.1 months (IQR: 7.7–29.1). The median SABR dose was 30 Gy (IQR 25–35 Gy). The most common primary histologies were Ewing sarcoma (25%), rhabdomyosarcoma (17%), osteosarcoma (13%), and central nervous system (CNS) gliomas (13%). Furthermore, 57% of patients had oligometastatic disease (≤5 lesions) at the time of SABR. The one-year LC, PFS, and OS rates were 94%, 22%, and 70%, respectively. No grade 4 or higher toxicities were observed, while the rates of any grade 1, 2, and 3 toxicities were 11.8%, 3.7%, and 4.4%, respectively. Patients with oligometastatic disease, lung, or brain metastases and those who underwent surgery for a metastatic site had a significantly longer PFS. LC at 1-year was significantly higher for patients with a sarcoma histology (95.7% vs. 86.5%, p = 0.01) and for those who received a biological equivalent dose (BED10) > 48 Gy (100% vs. 91.2%, p = 0.001). Conclusions: SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.
- Open Access
- 25 July 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (4) , 263-269
Natural Killer Cell Recognition and Control of Epithelial Cancers
Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and murine and human studies of each that are supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.
- 25 July 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (4) , 263-269
Open AccessNatural Killer Cell Recognition and Control of Epithelial Cancers
Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and murine and human studies of each that are supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.
- 1 May 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1133) , 20211088
Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors
Objective: The objective of this study is to report disease outcomes and toxicity with the use of stereotactic body radiation therapy (SBRT) in the treatment of pediatric metastatic disease. Methods: All pediatric and adolescent young adult (AYA) patients’ who received SBRT were included between the years 2000 and 2020. Study endpoints included local control (LC), progression-free survival (PFS), overall survival (OS), cumulative incidence (CI) of death or local failure and toxicity. The end points with respect to survival and LC were calculated using the Kaplan–Meier estimate. The cumulative incidence of local failure was calculated using death as a competing risk. Results: 16 patients with 36 lesions irradiated met inclusion criteria and formed the study cohort. The median OS and PFS for the entire cohort were 17 months and 15.7 months, respectively. The 1 year OS for the entire cohort was 75%. The 6- and 12 month local control was 85 and 78%, respectively. There were no local failures in irradiated lesions for patients who received a BED10≥100 Gy. Patients who were treated with SBRT who had ≤5 metastatic lesions at first recurrence had a superior 1 year OS of 100 vs 50% for those with >5 lesions. One patient (6.3%) experienced a Grade 3 central nervous system toxicity. Conclusion: LC was excellent with SBRT delivered to metastatic disease, particularly for lesions receiving a BED10≥100 Gy. High-grade toxicity was rare in our patient population. Patients with five or fewer metastatic sites have a significantly better OS compared to >5 sites. Advances in knowledge: This study demonstrates that SBRT is safe and efficacious in the treatment of pediatric oligometastatic disease.
- 1 May 2022
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1133) , 20211088
Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors
Objective: The objective of this study is to report disease outcomes and toxicity with the use of stereotactic body radiation therapy (SBRT) in the treatment of pediatric metastatic disease. Methods: All pediatric and adolescent young adult (AYA) patients’ who received SBRT were included between the years 2000 and 2020. Study endpoints included local control (LC), progression-free survival (PFS), overall survival (OS), cumulative incidence (CI) of death or local failure and toxicity. The end points with respect to survival and LC were calculated using the Kaplan–Meier estimate. The cumulative incidence of local failure was calculated using death as a competing risk. Results: 16 patients with 36 lesions irradiated met inclusion criteria and formed the study cohort. The median OS and PFS for the entire cohort were 17 months and 15.7 months, respectively. The 1 year OS for the entire cohort was 75%. The 6- and 12 month local control was 85 and 78%, respectively. There were no local failures in irradiated lesions for patients who received a BED10≥100 Gy. Patients who were treated with SBRT who had ≤5 metastatic lesions at first recurrence had a superior 1 year OS of 100 vs 50% for those with >5 lesions. One patient (6.3%) experienced a Grade 3 central nervous system toxicity. Conclusion: LC was excellent with SBRT delivered to metastatic disease, particularly for lesions receiving a BED10≥100 Gy. High-grade toxicity was rare in our patient population. Patients with five or fewer metastatic sites have a significantly better OS compared to >5 sites. Advances in knowledge: This study demonstrates that SBRT is safe and efficacious in the treatment of pediatric oligometastatic disease.
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 41 (4) , e206-e209
A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant
Myoepithelial carcinomas (MC) represent aggressive tumors that occur in a myriad of ages and anatomic locations. The rarity and histologic similarity with other tumors make them difficult to diagnosis. We report an extremely rare case of a right ventricular outflow tract mass identified to be an intracardiac MC in a 4-month-old male infant. Pathology revealed an EWS-KLF15 translocation. Treatment included gross total resection and intensive chemotherapy. Recurrent cardiac mass with brain metastasis was seen 16 months after primary diagnosis. We describe the rarity of intracardiac MC in pediatric patients and the challenges encountered in the multimodal management of this patient.
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 41 (4) , e206-e209
A Rare Case of an Intracardiac Myoepithelial Carcinoma in an Infant
Myoepithelial carcinomas (MC) represent aggressive tumors that occur in a myriad of ages and anatomic locations. The rarity and histologic similarity with other tumors make them difficult to diagnosis. We report an extremely rare case of a right ventricular outflow tract mass identified to be an intracardiac MC in a 4-month-old male infant. Pathology revealed an EWS-KLF15 translocation. Treatment included gross total resection and intensive chemotherapy. Recurrent cardiac mass with brain metastasis was seen 16 months after primary diagnosis. We describe the rarity of intracardiac MC in pediatric patients and the challenges encountered in the multimodal management of this patient.
- 2 February 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (8)
Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies
Therapy‐related thrombocytopenia (TRT), due to chemotherapy and/or radiation therapy, is common with pediatric cancer treatments, and it can result in dose reductions and therapy delays. Romiplostim, a thrombopoietin mimetic, is efficacious as a second‐line treatment for immune thrombocytopenia in children and for TRT in adult cancer patients. However, there are no data for its use for TRT in children. We report a case series of five children treated for solid tumors where romiplostim was used without adverse effects to successfully resolve and prevent therapy‐limiting refractory TRT. Prospective studies on this use of romiplostim are warranted.
- 2 February 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (8)
Romiplostim for therapy‐related thrombocytopenia in pediatric malignancies
Therapy‐related thrombocytopenia (TRT), due to chemotherapy and/or radiation therapy, is common with pediatric cancer treatments, and it can result in dose reductions and therapy delays. Romiplostim, a thrombopoietin mimetic, is efficacious as a second‐line treatment for immune thrombocytopenia in children and for TRT in adult cancer patients. However, there are no data for its use for TRT in children. We report a case series of five children treated for solid tumors where romiplostim was used without adverse effects to successfully resolve and prevent therapy‐limiting refractory TRT. Prospective studies on this use of romiplostim are warranted.
- Open Access
- 17 August 2016
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 9 (2) , 447-453
Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases
Pediatric soft tissue sarcomas of the oral/maxillofacial region are rare neoplasms that present significant difficulty with respect to treatment and local control measures. We report four cases of pediatric oral/maxillofacial soft tissue sarcomas from our tertiary care pediatric hospital and emphasize the rarity of these malignancies and the challenges encountered in treating these lesions, and suggest areas for further research. We conclude that multimodal therapy and interdisciplinary cooperation are paramount to successful management of these lesions.
- 17 August 2016
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 9 (2) , 447-453
Open AccessPediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases
Pediatric soft tissue sarcomas of the oral/maxillofacial region are rare neoplasms that present significant difficulty with respect to treatment and local control measures. We report four cases of pediatric oral/maxillofacial soft tissue sarcomas from our tertiary care pediatric hospital and emphasize the rarity of these malignancies and the challenges encountered in treating these lesions, and suggest areas for further research. We conclude that multimodal therapy and interdisciplinary cooperation are paramount to successful management of these lesions.
- 1 January 2015
- Published by Springer Nature
- p. 125-142
Histological Response and Biological Markers
- 1 January 2015
- Published by Springer Nature
- p. 211-219
Post-therapy Surveillance of Bone Tumors
- 25 May 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (3) , 514-515
Heterozygous M1V variant of ELA‐2 gene mutation associated with G‐CSF refractory severe congenital neutropenia
Severe congenital neutropenia is an autosomal recessive disorder characterized by maturation arrest at the promyelocyte/myelocyte phase in the bone marrow, absolute neutrophil count 9/L and recurrent bacterial infections. Homozygous mutations of either HAX‐1 or ELA‐2 have been described. We report the case of a premature male infant with congenital neutropenia, associated with multiple infections, refractory to treatment with granulocyte colony stimulating factor who subsequently underwent matched sibling donor stem‐cell transplant. He was found to be heterozygous for the M1V variant of the ELA‐2 gene that we postulate to be causative for his severe neutropenia. Pediatr Blood Cancer 2011; 57: 514–515.
- 25 May 2011
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (3) , 514-515
Heterozygous M1V variant of ELA‐2 gene mutation associated with G‐CSF refractory severe congenital neutropenia
Severe congenital neutropenia is an autosomal recessive disorder characterized by maturation arrest at the promyelocyte/myelocyte phase in the bone marrow, absolute neutrophil count 9/L and recurrent bacterial infections. Homozygous mutations of either HAX‐1 or ELA‐2 have been described. We report the case of a premature male infant with congenital neutropenia, associated with multiple infections, refractory to treatment with granulocyte colony stimulating factor who subsequently underwent matched sibling donor stem‐cell transplant. He was found to be heterozygous for the M1V variant of the ELA‐2 gene that we postulate to be causative for his severe neutropenia. Pediatr Blood Cancer 2011; 57: 514–515.
- 19 May 2010
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 5 (3) , 163-168
Rare Pediatric Non-Hodgkin Lymphoma
Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults. Understanding of these rare types of NHL comes from small pediatric case series or the adult literature. Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics. It is important to improve understanding and treatment of these rare pediatric NHLs through international collaborative efforts.
- 19 May 2010
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 5 (3) , 163-168
Rare Pediatric Non-Hodgkin Lymphoma
Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults. Understanding of these rare types of NHL comes from small pediatric case series or the adult literature. Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics. It is important to improve understanding and treatment of these rare pediatric NHLs through international collaborative efforts.